← All trials
NCT06861179
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 22, 2023
- Primary completion
- Dec 28, 2024
- Completion date
- Dec 28, 2024
- First posted
- Mar 6, 2025
- Last posted
- Mar 11, 2025
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Chinese Academy of Medical SciencesSponsor investigator
- Chinese Academy of Medical SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.